Regenerex Pharma (RGPX) Profit After Tax (2010 - 2025)

Regenerex Pharma (RGPX) has 13 years of Profit After Tax data on file, last reported at -$814011.0 in Q3 2025.

• Profit After Tax for Q3 2025 came in at -$814011.0, down 53.71% year-over-year; the trailing twelve-month figure through Sep 2025 was -$3.2 million (down 135.66% YoY), and the FY2025 annual result was -$2.5 million, up 28.69% from the prior year.
• Profit After Tax retreated to -$814011.0 in Q3 2025 per RGPX's latest filing, from -$663584.0 in the prior quarter.
• Over five years, Profit After Tax peaked at -$18436.0 in Q3 2022 and troughed at -$2.8 million in Q3 2023.
• A 5-year average of -$438147.8 and a median of -$224775.5 in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax plunged 15095.54% in 2023, then jumped 81.1% in 2024.
• A 5-year view of Profit After Tax shows it stood at -$78412.0 in 2021, then surged by 37.0% to -$49400.0 in 2022, then plunged by 434.36% to -$263976.0 in 2023, then fell by 19.15% to -$314526.0 in 2024, then sank by 158.81% to -$814011.0 in 2025.
• Business Quant data shows RGPX's Profit After Tax at -$814011.0 in Q3 2025, -$663584.0 in Q2 2025, and -$1.4 million in Q1 2025.